ABSTRACT
PURPOSE: To evaluate recovery of platelet count after transjugular intrahepatic portosystemic shunt (TIPS) creation and patient factors predicting platelet recovery after TIPS creation. MATERIALS AND METHODS: Adults with cirrhosis who underwent TIPS creation at 9 U.S. hospitals from 2010 to 2015 were included in this retrospective analysis. Change in platelets from before TIPS to 4 months after TIPS creation was characterized. Logistic regression was used to assess factors associated with top quartile percentage platelet increase after TIPS. Subgroup analyses were performed among patients with a pre-TIPS platelet count of ≤50 ×109/L. RESULTS: A total of 601 patients were included. The median absolute change in platelets was 1 × 109/L (-26 × 109/L to 25 × 109/L). Patients with top quartile percent platelet increase experienced ≥32% platelet increase. In multivariable analysis, pre-TIPS platelet counts (odds ratio [OR], 0.97 per 109/L; 95% CI, 0.97-0.98), age (OR, 1.24 per 5 years; 95% CI, 1.10-1.39), and pre-TIPS model for end-stage liver disease (MELD) scores (OR, 1.06 per point; 95% CI, 1.02-1.09) were associated with top quartile (≥32%) platelet increase. Ninety-four (16%) patients had a platelet count of ≤50 × 109/L before TIPS. The median absolute platelet change was 14 × 109/L (2 × 109/L to 34 × 109/L). Fifty-four percent of patients in this subgroup were in the top quartile for platelet increase. In multivariable logistic regression, age (OR, 1.50 per 5 years; 95% CI, 1.11-2.02) was the only factor associated with top quartile platelet increase in this subgroup. CONCLUSIONS: TIPS creation did not result in significant platelet increase, except among patients with a platelet count of ≤50 × 109/L before TIPS. Lower pre-TIPS platelet counts, older age, and higher pre-TIPS MELD scores were associated with top quartile (≥32%) platelet increase in the entire cohort, whereas only older age was associated with this outcome in the patient subset with a pre-TIPS platelet count of ≤50 × 109/L.
Subject(s)
End Stage Liver Disease , Portasystemic Shunt, Transjugular Intrahepatic , Adult , Humans , Child, Preschool , Platelet Count , Retrospective Studies , Portasystemic Shunt, Transjugular Intrahepatic/adverse effects , Severity of Illness Index , Liver Cirrhosis/diagnosis , Liver Cirrhosis/surgery , Liver Cirrhosis/complications , Treatment OutcomeABSTRACT
Complications of portal hypertension, including ascites, gastrointestinal bleeding, hepatic hydrothorax, and hepatic encephalopathy, are associated with significant morbidity and mortality. Despite few high-quality randomized controlled trials to guide therapeutic decisions, transjugular intrahepatic portosystemic shunt (TIPS) creation has emerged as a crucial therapeutic option to treat complications of portal hypertension. In North America, the decision to perform TIPS involves gastroenterologists, hepatologists, and interventional radiologists, but TIPS creation is performed by interventional radiologists. This is in contrast to other parts of the world where TIPS creation is performed primarily by hepatologists. Thus, the successful use of TIPS in North America is dependent on a multidisciplinary approach and technical expertise, so as to optimize outcomes. Recently, new procedural techniques, TIPS stent technology, and indications for TIPS have emerged. As a result, practices and outcomes vary greatly across institutions and significant knowledge gaps exist. In this consensus statement, the Advancing Liver Therapeutic Approaches group critically reviews the application of TIPS in the management of portal hypertension. Advancing Liver Therapeutic Approaches convened a multidisciplinary group of North American experts from hepatology, interventional radiology, transplant surgery, nephrology, cardiology, pulmonology, and hematology to critically review existing literature and develop practice-based recommendations for the use of TIPS in patients with any cause of portal hypertension in terms of candidate selection, procedural best practices and, post-TIPS management; and to develop areas of consensus for TIPS indications and the prevention of complications. Finally, future research directions are identified related to TIPS for the management of portal hypertension.
Subject(s)
Esophageal and Gastric Varices , Hypertension, Portal , Portasystemic Shunt, Transjugular Intrahepatic , Ascites/etiology , Esophageal and Gastric Varices/complications , Gastrointestinal Hemorrhage/complications , Gastrointestinal Hemorrhage/surgery , Humans , Hypertension, Portal/complications , Hypertension, Portal/surgery , Portasystemic Shunt, Transjugular Intrahepatic/adverse effects , Treatment OutcomeABSTRACT
Intravenous (IV) contrast material is used extensively for CT and MRI scans done in emergency departments (ED). Its use is essential to make many critical diagnoses in ED patients. While adverse reactions can occur, newer research has added to our knowledge of IV contrast media tolerance and safety leading to improved and more liberal guidelines for intravenous contrast use. The updated information described in this review article indicates how intravenous contrast can be used safely in more patients, more expeditiously and with fewer precautions than with prior guidelines. This review article explains the basis for the new recommendations for intravenous contrast material use and describes indicated precautions and preparations to avoid adverse reactions for iodinated agents used for CT and gadolinium agents for MRI.
Subject(s)
Contrast Media/administration & dosage , Emergency Service, Hospital , Magnetic Resonance Imaging , Practice Guidelines as Topic , Tomography, X-Ray Computed , Contrast Media/adverse effects , Drug Hypersensitivity/etiology , Drug Hypersensitivity/prevention & control , Gadolinium/administration & dosage , Gadolinium/adverse effects , Humans , Injections, Intravenous , Risk Factors , Safety ManagementABSTRACT
PURPOSE: To evaluate efficacy and safety of transjugular liver biopsy (TJLB) via the left hepatic vein in patients with left lobe-only liver transplants (LLOTs). MATERIALS AND METHODS: Retrospective review revealed 43 TJLBs performed in 26 patients with LLOTs (mean age 51.3 y; range, 18-73 y) between January 2009 and June 2016 at a single institution. A comparison group of 44 randomly selected TJLBs performed in 37 orthotopic whole liver transplant (OWLT) recipients (mean age 57.6 y; range, 35-74 y) during the same time period was evaluated. Patient demographics, type and age of transplant, technical success, adequacy of samples, number of portal tracts obtained, pathologic diagnosis, and complication rate were reviewed. RESULTS: Technical success was achieved in 98% (42/43) of LLOT procedures. TJLB failed in 1 patient with LLOT, in whom no patent hepatic veins were identified. Technical success was achieved in 100% (44/44) in the OWLT group. Mean (SD) number of needle passes was 4.12 (1.25) in the LLOT group vs 3.95 (1.28) in the OWLT group (P = .54). Mean (SD) specimen length was 1.16 (0.75) cm in the LLOT group vs 1.19 (0.58) cm in the OWLT group (P = .78). Mean (SD) number of portal tracts obtained in the LLOT group was 10.7 (5.26) vs 12.3 (4.68) in the OWLT group (P = .17). No major complications were observed in either group. CONCLUSIONS: TJLB in adult patients with LLOTs appears safe and feasible, with favorable rates of technical success and adequacy of sampling.
Subject(s)
Biopsy, Needle/methods , Catheterization, Central Venous/methods , Hepatic Veins , Image-Guided Biopsy/methods , Jugular Veins , Liver Transplantation , Postoperative Complications/pathology , Adolescent , Adult , Aged , Angiography, Digital Subtraction , Biopsy, Needle/adverse effects , Catheterization, Central Venous/adverse effects , Female , Hepatic Veins/diagnostic imaging , Humans , Image-Guided Biopsy/adverse effects , Jugular Veins/diagnostic imaging , Liver Transplantation/adverse effects , Male , Middle Aged , Phlebography , Postoperative Complications/etiology , Predictive Value of Tests , Radiography, Interventional , Retrospective Studies , Risk Assessment , Risk Factors , Young AdultABSTRACT
PURPOSE: To assess the effectiveness of disposable radiation-absorbing surgical drapes on operator radiation dose during transjugular liver biopsy (TJLB). MATERIALS AND METHODS: This dual-arm prospective, randomized study was conducted between May 2017 and January 2018 at a single institution. TJLB procedures (N = 62; patient age range, 19-80 y) were assigned at a 1:1 ratio to the use of radiation-absorbing surgical drapes or standard surgical draping. The primary outcome was cumulative radiation equivalent dose incident on the operator, as determined by an electronic personal dosimeter worn at the chest during each procedure. Cumulative kerma-area product (KAP), total fluoroscopy time, and total number of exposures used during each liver biopsy procedure were also determined. RESULTS: Mean radiation dose incident on the operator decreased by 56% with the use of radiation-absorbing drapes (37 µSv ± 35; range, 4-183 µSv) compared with standard draping (84 µSv ± 58; range, 11-220 µSv). Radiation incident on the patient was similar between groups, with no significant differences in mean KAP, total fluoroscopy time, and number of exposures acquired during the procedures. CONCLUSIONS: Use of disposable radiation-absorbing drapes reduces scatter radiation to interventionalists performing TJLB.
Subject(s)
Image-Guided Biopsy/instrumentation , Liver Diseases/diagnostic imaging , Occupational Exposure/prevention & control , Occupational Health , Radiation Exposure/prevention & control , Radiation Protection/instrumentation , Radiography, Interventional/instrumentation , Radiologists , Surgical Drapes , Adult , Aged , Aged, 80 and over , Disposable Equipment , Female , Humans , Image-Guided Biopsy/adverse effects , Liver Diseases/pathology , Male , Middle Aged , Occupational Exposure/adverse effects , Pilot Projects , Prospective Studies , Protective Factors , Radiation Dosage , Radiation Dosimeters , Radiation Exposure/adverse effects , Radiography, Interventional/adverse effects , Risk Factors , San Francisco , Scattering, Radiation , Young AdultABSTRACT
PURPOSE: To assess radiation dose reduction during uterine fibroid embolization (UFE) using an optimized angiographic processing and acquisition platform. MATERIALS AND METHODS: Radiation dose data for 70 women (mean age, 46 y; range, 34-67 y) who underwent UFE were retrospectively analyzed. Twenty-one patients underwent UFE using the baseline fluoroscopic and angiographic image acquisition platform, and 49 underwent UFE after implementing an optimized imaging platform in otherwise identical angiography suites. Cumulative kerma-area product (CKAP), cumulative air kerma (CAK), total fluoroscopy time, and image exposure number were collected for each procedure. Image quality was assessed by 3 interventional radiologists blinded to the platform used for image acquisition and processing. RESULTS: Patients undergoing UFE using the new x-ray fluoroscopy platform had significantly lower CKAP and CAK indicators than patients for whom baseline settings were used. Mean CKAP decreased by 60% from 438.5 Gy · cm2 (range, 180.3-1,081.1 Gy · cm2) to 175.2 Gy · cm2 (range, 47.1-757.0 Gy · cm2; P < .0001). Mean CAK decreased by 45% from 2,034.2 mGy (range, 699.3-5,056.0 mGy) to 1,109.8 mGy (range, 256.6-4,513.6 mGy; P = .001). No degradation of image quality was identified through qualitative evaluation. CONCLUSIONS: Significant reduction in patient radiation dose indicators can be achieved with use of an optimized image acquisition and processing platform.
Subject(s)
Embolization, Therapeutic/methods , Leiomyoma/diagnostic imaging , Leiomyoma/therapy , Radiation Protection/methods , Radiography, Interventional , Uterine Neoplasms/diagnostic imaging , Uterine Neoplasms/therapy , Adult , Aged , Angiography, Digital Subtraction , Female , Fluoroscopy , Humans , Middle Aged , Radiation Dosage , Retrospective Studies , Tomography, X-Ray Computed , Treatment OutcomeABSTRACT
PURPOSE: To assess safety and efficacy of doxorubicin drug-eluting embolic (DEE) transarterial chemoembolization of hepatocellular carcinoma (HCC) by extrahepatic collateral arteries. MATERIALS AND METHODS: Records of 177 patients with HCC who underwent 338 consecutive DEE chemoembolization procedures from 2011 to 2014 were retrospectively reviewed. A subgroup of 16 patients (13 men, 3 women, median age 66 y) underwent 24 procedures for 17 HCCs via extrahepatic arteries and was included in the study. Median tumor size was 3.1 cm (range, 1.0-10.3 cm). Extrahepatic collaterals included right inferior phrenic (19 procedures; 12 patients), adrenal (4 procedures; 3 patients), and cystic arteries (2 procedures; 2 patients). Radiographic response was assessed by Modified Response Evaluation Criteria in Solid Tumors criteria. Complications were defined by National Cancer Institute Common Terminology Criteria for Adverse Events. RESULTS: DEE chemoembolization achieved stable disease in 6 (35.3%), partial response in 6 (35.3%), and complete response in 4 (23.5%) HCCs. Disease progression was ultimately observed in 8 tumors (47.1%), with mean time to progression of 8.3 months after chemoembolization (range, 2-13 mo). Three minor and 5 major complications occurred in 8 patients; 2 minor complications were rash in vascular distribution after right inferior phrenic artery DEE chemoembolization. The 5 major complications were transient hepatotoxicity that resolved within 4-80 days; 1 was accompanied by pleural effusion requiring hospitalization. A mean 13.4 months after DEE chemoembolization, 67% of transplant candidates proceeded to liver transplant. CONCLUSIONS: DEE transarterial chemoembolization via extrahepatic collaterals was effective and facilitated bridging to transplant. It was generally well tolerated; transient hepatotoxicity was the most common major complication.
Subject(s)
Antibiotics, Antineoplastic/administration & dosage , Carcinoma, Hepatocellular/blood supply , Carcinoma, Hepatocellular/therapy , Chemoembolization, Therapeutic/methods , Collateral Circulation , Doxorubicin/administration & dosage , Liver Circulation , Liver Neoplasms/blood supply , Liver Neoplasms/therapy , Aged , Aged, 80 and over , Angiography, Digital Subtraction , Antibiotics, Antineoplastic/adverse effects , Carcinoma, Hepatocellular/diagnostic imaging , Chemoembolization, Therapeutic/adverse effects , Computed Tomography Angiography , Disease Progression , Doxorubicin/adverse effects , Female , Humans , Liver Neoplasms/diagnostic imaging , Liver Transplantation , Male , Middle Aged , Retrospective Studies , Time Factors , Treatment OutcomeSubject(s)
Betacoronavirus , Coronavirus Infections/diagnostic imaging , Pneumonia, Viral/diagnostic imaging , Radiology Department, Hospital/organization & administration , COVID-19 , Coronavirus Infections/prevention & control , Coronavirus Infections/transmission , Cross Infection/prevention & control , Expert Testimony , Health Priorities , Humans , Infection Control/organization & administration , Infectious Disease Transmission, Patient-to-Professional/prevention & control , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Pneumonia, Viral/transmission , SARS-CoV-2 , Tomography, X-Ray ComputedABSTRACT
The goal of this study was to determine whether the detection of discordant numbers of hypervascular foci at hepatic angiography versus contrast-enhanced (CE) cross-sectional imaging [computed tomography (CT) or magnetic resonance imaging (MRI)] is associated with adverse clinical outcomes in patients with hepatocellular carcinoma (HCC) who are listed for liver transplantation. We retrospectively reviewed the records of 218 consecutive patients with HCC who were listed for a liver transplant and who underwent transarterial chemoembolization at our institution between January 1, 2006 and December 31, 2010. Patients were grouped into 3 categories: (1) the number of nodules at CT/MRI was concordant with the number of hypervascular foci detected at angiography (n=136), (2) the number of nodules at CT/MRI was greater than the number of hypervascular foci at angiography (n=45), and (3) the number of nodules at CT/MRI was fewer than the number of hypervascular foci at angiography (n=37). The study outcomes were liver transplantation and tumor recurrence after transplantation. The detection of at least 3 more hypervascular foci at angiography versus the number of HCC nodules on CT/MRI was associated with a significantly lower rate of transplantation [multivariate subhazard ratio (SHR), 0.39; 95% confidence interval (CI), 0.17-0.92]. The detection of fewer hypervascular foci at angiography versus the number of HCC nodules on CT/MRI was associated with a significantly higher rate of tumor recurrence after transplantation (multivariate SHR, 3.49; 95% CI, 1.27-9.56). In conclusion, liver transplant candidates with HCC who demonstrate discordant findings between angiography and CE CT or MRI may be at a higher risk for dropout from the transplant list and for tumor recurrence after transplantation.
Subject(s)
Angiography, Digital Subtraction , Carcinoma, Hepatocellular/diagnosis , Decision Support Techniques , Liver Neoplasms/diagnosis , Liver Transplantation , Magnetic Resonance Imaging , Patient Selection , Tomography, X-Ray Computed , Adult , Aged , Carcinoma, Hepatocellular/diagnostic imaging , Carcinoma, Hepatocellular/pathology , Carcinoma, Hepatocellular/surgery , Contrast Media , Female , Humans , Liver Neoplasms/diagnostic imaging , Liver Neoplasms/pathology , Liver Neoplasms/surgery , Liver Transplantation/adverse effects , Logistic Models , Male , Middle Aged , Multivariate Analysis , Neoplasm Recurrence, Local , Predictive Value of Tests , Retrospective Studies , Risk Assessment , Risk Factors , San Francisco , Time Factors , Treatment Outcome , Young AdultSubject(s)
Angioplasty, Balloon/instrumentation , Graft Occlusion, Vascular/therapy , Iliac Vein/transplantation , Liver Transplantation/adverse effects , Mesenteric Veins/surgery , Portal Vein/surgery , Self Expandable Metallic Stents , Vascular Diseases/surgery , Vascular Grafting/adverse effects , Alloys , Constriction, Pathologic , Graft Occlusion, Vascular/diagnostic imaging , Graft Occlusion, Vascular/etiology , Graft Occlusion, Vascular/physiopathology , Humans , Iliac Vein/diagnostic imaging , Iliac Vein/physiopathology , Male , Mesenteric Veins/diagnostic imaging , Mesenteric Veins/physiopathology , Portal Vein/diagnostic imaging , Portal Vein/physiopathology , Prosthesis Design , Treatment Failure , Vascular Diseases/diagnostic imaging , Vascular Diseases/etiology , Vascular Diseases/physiopathology , Vascular Patency , Young AdultABSTRACT
PURPOSE: To evaluate radiation dose reduction in patients undergoing transarterial chemoembolization with the use of a new image acquisition and processing platform. MATERIALS AND METHODS: Radiation-dose data were obtained from 176 consecutive chemoembolization procedures in 135 patients performed in a single angiography suite. From January 2013 through October 2013, 85 procedures were performed by using our institution's standard fluoroscopic settings. After upgrading the x-ray fluoroscopy system with an image acquisition and processing platform designed to reduce image noise and reduce skin entrance dose, 91 chemoembolization procedures were performed from November 2013 through December 2014. Cumulative dose-area product (CDAP), cumulative air kerma (CAK), and total fluoroscopy time were recorded for each procedure. Image quality was assessed by three interventional radiologists blinded to the x-ray acquisition platform used. RESULTS: Patient radiation dose indicators were significantly lower for chemoembolization procedures performed with the novel imaging platform. Mean CDAP decreased from 3,033.2 dGy·cm(2) (range, 600.3-9,404.1 dGy·cm(2)) to 1,640.1 dGy·cm(2) (range, 278.6-6,779.9 dGy·cm(2); 45.9% reduction; P < .00001). Mean CAK decreased from 1,445.4 mGy (range, 303.6-5,233.7 mGy) to 971.7 mGy (range, 144.2-3,512.0 mGy; 32.8% reduction; P < .0001). A 20.3% increase in mean total fluoroscopy time was noted after upgrading the imaging platform, but blinded analysis of the image quality revealed no significant degradation. CONCLUSIONS: Although a small increase in fluoroscopy time was observed, a significant reduction in patient radiation dose was achieved by using the optimized imaging platform, without image quality degradation.
Subject(s)
Angiography/instrumentation , Chemoembolization, Therapeutic/instrumentation , Fluoroscopy/instrumentation , Radiation Dosage , Radiation Protection/instrumentation , Radiography, Interventional/instrumentation , Adult , Aged , Aged, 80 and over , Equipment Design , Equipment Failure Analysis , Female , Humans , Male , Middle Aged , Reproducibility of Results , Retrospective Studies , Sensitivity and Specificity , Young AdultABSTRACT
BACKGROUND: Right adrenal vein (RAV) catheterization can be a very challenging step in adrenal venous sampling (AVS). Visualization of the inferior emissary vein (IEV) may be an indication of successful RAV catheterization. PURPOSE: To compare the rate of successful RAV sampling in the presence of the IEV. MATERIAL AND METHODS: Retrospective review of all consecutive patients with PA who underwent AVS between April 2009 and April 2012 was performed. A total of 30 patients were identified. Procedural images, cortisol, and aldosterone values obtained from sampling of the RAV and inferior vena cava (IVC) were reviewed. Cortisol measurements obtained from RAV samples were divided by measurements from the infra-renal IVC blood samples in order to calculate the selectivity index (SI). An SI >3 was considered indicative of technically successful RAV sampling. RESULTS: RAV sampling was considered technically successful in 29 out of 30 cases (97%). In cases of successful RAV sampling (29 patients), the IEV was identified in 25 patients (86%). The IEV was visualized in isolation in 16 patients (64%), and in conjunction with visualization of the RAV or right adrenal gland stain in nine patients (36%). The IEV was not visualized in the one case of unsuccessful RAV sampling. Visualizing the IEV had a sensitivity of 86.2% for successful RAV sampling. CONCLUSION: The IEV may serve as a reliable landmark for the RAV during RAV sampling.
Subject(s)
Adrenal Glands/blood supply , Blood Specimen Collection/methods , Catheterization, Peripheral/methods , Radiography, Interventional/methods , Veins/anatomy & histology , Adolescent , Adult , Aged , Female , Humans , Hydrocortisone/blood , Male , Middle Aged , Retrospective Studies , Sensitivity and Specificity , Young AdultABSTRACT
PURPOSE: To determine clinical outcomes of patients who underwent imaging-guided percutaneous drainage of breast fluid collections after mastectomy and breast reconstruction. MATERIALS AND METHODS: A retrospective review was performed including all consecutive patients who underwent percutaneous drainage of fluid collections after mastectomy with tissue expander-based reconstruction between January 2007 and September 2012. During this period, 879 mastectomies (563 patients) with expander-based breast reconstruction were performed. Fluid collections developed in 28 patients (5%), which led to 30 imaging-guided percutaneous drainage procedures. The median follow-up time was 533 days. Patient characteristics, surgical technique, microbiology analysis, and clinical outcomes were reviewed. RESULTS: The mean age of patients was 51.5 years (range, 30.9-69.4 y), and the median time between breast reconstruction and drainage was 35 days (range, 4-235 d). Erythema and swelling were the most common presenting symptoms. The median volume of fluid evacuated at the time of drain placement was 70 mL. Drains were left in place for a median 14 days (range, 6-34 d). Microorganisms were detected in the fluid in 12 of 30 drainage procedures, with Staphylococcus aureus being the most common microorganism. No further intervention was needed in 21 of 30 drainage procedures (70%). However, surgical intervention (removal of expanders) was needed after 6 (20%) drainage procedures, and additional percutaneous drainage procedures were performed after 3 (10%) drainage procedures. CONCLUSIONS: Percutaneous drainage is an effective means of treating postoperative fluid collections after expander-based breast reconstruction and can obviate the need for repeat surgery in most cases.
Subject(s)
Breast Diseases/epidemiology , Breast Diseases/surgery , Breast Implants/statistics & numerical data , Drainage/statistics & numerical data , Mastectomy/statistics & numerical data , Postoperative Complications/epidemiology , Postoperative Complications/surgery , Adult , Aged , Body Fluids/cytology , Exudates and Transudates/cytology , Female , Humans , Male , Middle Aged , Prevalence , Plastic Surgery Procedures/statistics & numerical data , Retrospective Studies , Risk Factors , San Francisco/epidemiology , Treatment OutcomeABSTRACT
PURPOSE: We sought to identify which aspects of the referring clinician experience are most strongly correlated with overall satisfaction, and hence of greatest relevant importance to referring clinicians. METHODS: A survey instrument assessing referring clinician satisfaction throughout 11 domains of the radiology process map was distributed 2720 clinicians. The survey contained sections assessing each process map domain, with each section including a question about satisfaction overall in that domain and multiple more granular questions. The final question on the survey was overall satisfaction with the department. Univariate logistic regression and multivariate logistic regression were performed to assess the association between individual survey questions and overall satisfaction with the department. RESULTS: 729 referring clinicians (27%) completed the survey. Using univariate logistic regression nearly every question was associated with overall satisfaction. Amongst the 11 domains of the radiology process map multivariate logistic regression identified the following as mostly strongly associated with overall satisfaction: results/reporting overall (odds ratio 4.71; 95% confidence interval 2.15-10.23), section with which work most closely overall (3.39; 1.28-8.64), and inpatient radiology overall (2.39; 1.08-5.08). Other survey questions associated with overall satisfaction on multivariate logistic regression were attending radiologist interactions (odds ratio 3.71; 95% confidence interval 1.54-8.69), timeliness of inpatient radiology results (2.91; 1.01-8.09), technologist interactions (2.15; 0.99-4.40), appointment availability for urgent outpatient studies (2.01; 1.08-3.64), and guidance for selecting correct imaging study (1.88; 1.04-3.34). CONCLUSION: Referring clinicians value most the accuracy of the radiology report and their interactions with attending radiologists, particularly within the section they work most closely.
Subject(s)
Radiology , Humans , Radiology/methods , Radiography , Diagnostic Imaging , Surveys and Questionnaires , RadiologistsABSTRACT
The purpose of this study was to test the potential of clinical imaging modalities, 64-slice multidetector computed tomography (MDCT) and 1.5T magnetic resonance imaging (MRI) for qualitative and quantitative evaluation of acute microinfarcts and to determine the effects of <120 µm microemboli on left ventricular function, perfusion, cardiac injury biomarkers, arrhythmia, and cellular and vascular structures. Under X-ray fluoroscopy, 40-120 µm (16 mm(3) ) microemboli were delivered to embolize the left anterior descending (LAD) coronary artery of nine pigs. MDCT/MRI were performed at 72 h in a single session. Microinfarcts were visible in six of nine animals on delayed contrast-enhanced MDCT/MR images but measurable in all animals using semiautomated threshold methods. Other MDCT and MRI sequences demonstrated decline in left ventricular ejection fraction, regional strain and perfusion in visible and invisible microinfarcted regions. Microemboli caused significant elevation in cardiac injury enzymes and arrhythmias. Various sizes of microinfarcts appeared microscopically as distinct aggregates of macrophages replacing myocardium. Semiautomated threshold methods are necessary to measure and confirm/deny the presence of myocardial microinfarcts. This study offers support for alternative applications of MDCT/MRI in assessing clinical cases in which microemboli <120 µm escape protective devices during percutaneous coronary interventions. Although microembolization resulted in no mortality, it caused left ventricular dysfunction, perfusion deficit, cellular damage increase in cardiac injury enzymes, and arrhythmias.
Subject(s)
Coronary Artery Disease/diagnosis , Embolism/diagnosis , Magnetic Resonance Imaging/methods , Myocardial Infarction/diagnosis , Tomography, X-Ray Computed/methods , Ventricular Dysfunction, Left/diagnosis , Animals , Reproducibility of Results , Sensitivity and Specificity , SwineABSTRACT
PURPOSE: To determine the safety and feasibility of pancreatic retrograde venous infusion (PRVI) utilizing a microvalvular infusion system (MVI) to deliver ethiodized oil (lipiodol) by means of the Pressure-Enabled Drug Delivery (PEDD) approach. METHODS: Utilizing transhepatic access, mapping of the pancreatic body and head venous anatomy was performed in 10 swine. PEDD was performed by cannulation of veins in the head (n = 4) and body (n = 10) of the pancreas with a MVI (Surefire® Infusion System (SIS), Surefire Medical, Inc (DBA TriSalus™ Life Sciences)) followed by infusion with lipiodol. Sets of animals were killed either immediately (n = 8) or at 4 days post-PRVI (n = 2). All pancreata were harvested and studied with micro-CT and histology. We also performed three-dimensional volumetric/multiplanar imaging to assess the vascular distribution of lipiodol within the glands. RESULTS: A total of 14 pancreatic veins were successfully infused with an average of 1.7 (0.5-2.0) mL of lipiodol. No notable change in serum chemistries was seen at 4 days. The signal-to-noise ratio (SNR) of lipiodol deposition was statistically increased both within the organ in target relative to non-target pancreatic tissue and compared to extra pancreatic tissue (p < 0.05). Histological evaluation demonstrated no evidence of pancreatic edema or ischemia. CONCLUSIONS: PEDD using the RVI approach for targeted pancreatic infusions is technically feasible and did not result in organ damage in this pilot animal study.
Subject(s)
Drug Delivery Systems , Ethiodized Oil/administration & dosage , Pancreas/drug effects , Animals , Antineoplastic Agents/administration & dosage , Infusions, Intravenous , Models, Animal , Pressure , SwineSubject(s)
Device Removal/methods , Foreign Bodies/surgery , Needles , Obstetric Labor Complications/surgery , Perineum/surgery , Suture Techniques/instrumentation , Adult , Female , Foreign Bodies/diagnostic imaging , Humans , Obstetric Labor Complications/diagnosis , Perineum/diagnostic imaging , Pregnancy , Radiography, Interventional , Tomography, Spiral Computed , Treatment OutcomeABSTRACT
Purpose: To determine whether chemoembolization using drug-eluting beads (DEB-TACE) is safe and effective for liver transplantation candidates with liver-limited hepatocellular carcinoma (HCC) without vascular invasion and baseline hepatic dysfunction. Materials and methods: Seventeen adult liver transplantation candidates (median age 66 years, range 58-73 years; 13 men) with HCC were treated with DEB-TACE as a part of Stage 1 of a prospective single-institution Phase II trial. All patients had marginal hepatic reserve based on at least one of the following criteria: ascites (n=14), bilirubin between 3 and 6 mg/dL (n=5), AST 5-10 times upper normal limit (n=1), INR between 1.6 and 2.5 (n=4), portal vein thrombosis (n=2), and/or portosystemic shunt (n=2). Primary study objectives were safety and best observed radiographic response. Results: Thirty-seven DEB-TACE procedures were performed. Objective response rate and disease control rate were 63% and 88%, respectively. HCC progression was observed in 12 patients. Median time to progression was 5.6 months (range 0.9-13.6 months). Within 1 month following DEB-TACE, 13 patients (76%) developed grade 3 or 4 AE attributable to the procedure. Four patients (all within Milan Criteria) were transplanted (2.7-6.9 months after DEB-TACE), and 12 patients died (1.8-32 months after DEB-TACE). All deaths were due to liver failure that was either unrelated to HCC (n=5), in the setting of metastatic HCC (n=5), or in the setting of locally advanced HCC (n=2). Mortality rate at 1 month was 0%. Conclusions: DEB-TACE achieves tumor responses but carries a high risk of hepatotoxicity for liver transplant candidates with HCC and marginal hepatic reserve.